Physician profile
Chloe E Simmons
NPI 1952953051
$2,781.91
in general payments reported to CMS, 2019-2025
28 companies · $96.34 in 2025
The $96.34 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,541 · 2022: $1,012 · 2023: $105 · 2024: $27.99 · 2025: $96.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $229.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $532.75 | 2021-2025 | Wegovy |
| Abbvie INC. | $433.96 | 2021-2024 | |
| Lilly USA, LLC | $326.50 | 2021-2023 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $190.27 | 2021-2023 | Breztri |
| Merck Sharp & Dohme LLC | $130.16 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $127.83 | 2022 | |
| Glaxosmithkline, LLC. | $104.96 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.58 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $86.70 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $74.58 | 2021 | |
| Insulet Corporation | $68.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.92 | 2021-2023 | Ofev |
| Eisai INC. | $55.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $54.51 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $50.74 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $47.70 | 2021 | |
| Pfizer INC. | $47.12 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $36.99 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.80 | 2021-2022 | |
| Dexcom, INC. | $33.98 | 2021-2022 | |
| Lundbeck LLC | $20.62 | 2022 | |
| Medtronic, INC. | $18.62 | 2022 | |
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Avanir Pharmaceuticals, INC. | $16.72 | 2021 | |
| Sanofi Pasteur INC. | $14.18 | 2022 | |
| Genentech USA, INC. | $8.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.